The author's market research report predicts that the “Global Lung Cancer Drugs Market” will grow at a CAGR of 13.6% during the forecast period. The market has witnessed steady growth in the past few years with the introduction of novel products, which have augmented the acceptance of immunotherapy drugs in the market. The market is fueled by upsurge in the incidence of lung cancer cases across the globe – owing to increasing diagnosis rate and mainly due to increasing tobacco consumption, increase in the lung cancer treatment rates, increasing rate of effective drug approvals as first-line therapies, strategic deals to develop new products, increasing R&D spending, and rapid industrialization leading to increased pollution.
The leading global pharmaceutical companies are focusing on product approvals as first-line treatment therapy and combination treatment with chemotherapy, collaborations, and regulatory submission of already matured cancer treatments in the developing countries as a major strategy to increase their revenue. Many of the global players are also focusing on providing home infusion services in the developed markets with secured and safe cold chain logistic infrastructure. This Direct-to-Patient (DTP) strategy is also helping market players to expand their patient volumes and thus the overall revenues globally. The market generates the revenue from the key players operating in this field and some of them include, F. Hoffmann-La Roche Ltd, Bristol–Myers Squibb, Janssen, Amgen, AstraZeneca PLC, Pfizer, Inc., Eli Lilly & Company Ltd, and Novartis AG.
According to the author's analysis, North America accounted for the largest share of the global lung cancer drugs market in 2018 and will retain a high position during the forecast period 2019–2025. According to WHO, cancer accounted for an estimated 9.6 million deaths in 2018 and the most common cancer among all types is lung cancer (2.09 million cases). An estimated 234,030 new cases of lung cancer were diagnosed in 2018, representing about 13% of all cancer diagnoses in the country.
Europe is the second major shareholder of the global lung cancer drugs market. There were an estimated 3.91 million new cases of cancer and 1.93 million deaths from cancer in 2018. Lung cancer is the third most common cancer type of cancer (470,000) after the female breast cancer and colorectal cancer (500,000). In the UK, around 46,700 new lung cancer cases are recorded annually and it is the third most common cancer. The Asia Pacific is expected to grow at high double digit CAGR during the forecast period, owing to factors such as the increasing prevalence of cancer cases, growing healthcare expenditure, and increased healthcare awareness.
By Disease Type:
- Small cell lung cancer (SCLC)
- Non-small cell lung cancer (NSCLC)
The non-small cell lung cancer segment occupied the largest share in 2018 and is expected to grow at mid-double digit CAGR during the forecast period. The increasing incidence and prevalence of non-small cell lung cancer and rapid industrialization make the segment the fastest growing during the forecast period 2019–2025.
By Molecule Type:
- Small molecules
In 2018, the small molecules segment occupied the largest share and biologics is expected to grow at a high CAGR during the forecast period due to increasing adoption of biologics, strong pipeline targeting first-line treatments, and recent product approvals.
- North America
North America is dominant in the global lung cancer drugs market followed by Europe and Asia Pacific. The significant share of the North America market comes from the US due to the availability of favourable reimbursement policies.
Lung Cancer Drugs Market Research Competitive Analysis – The global lung cancer drugs market has massive growth opportunities in both developed and developing regions. Many companies are concentrating on new approvals, collaborations, and development of new drugs to treat lung cancer due to an increase in the incidence of cancer and the need for advanced treatments. For instance, the European Commission has approved brigatinib (Alunbrig) developed by Takeda Pharmaceutical in November 2018 to treat adult patients with ALK-positive non–small cell lung cancer (NSCLC) who were previously treated with crizotinib (Xalkori). FDA approved durvalumab (Imfinzi) developed by AstraZeneca Inc. in February 2018 for the treatment of unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. In addition, other leading vendors are focusing on investing huge on research and development activities to develop new products to obtain a high share in the market.
- F. Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- Bristol–Myers Squibb
- Pfizer, Inc.
- Eli Lilly and Company Ltd.
- Novartis AG
Key Competitive Facts
Increasing incidence of the disease globally, promising drug pipeline, and enormous R&D activities for lung cancer drug development are the major factors driving the market growth.
The pipeline of oncology drugs in the clinical development has expanded by 45% over the past 10 years; 87% of the late-stage pipeline is targeted therapies, which include small molecule protein kinase inhibitors and biologic monoclonal antibodies.
The report provides complete details about the sub-segments of the lung cancer drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals and to analyze before investing or expanding the business in this market.
- Understanding the potential market opportunity with precise market size and forecast data.
- A detailed market analysis focusing on the growth of lung cancer drugs industry.
- Factors influencing the growth of the lung cancer drugs market.
- In-depth competitive analysis of dominant and pure-play vendors.
- Prediction analysis of the lung cancer drugs market in both developed and developing regions.
- Key insights related to major segments of the lung cancer drugs market.
- Latest market trend analysis impacting the buying behaviour of the consumers.
Table of Contents
1.1.1 Top Pharma Drugs by Sales ($Million)
1.2 Industry Trends
1.3 Total Addressable Market
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3.2 Segmented Addressable Market (SAM)
3.3 Trends of the Lung Cancer Drugs Market
3.4 Related Markets
3.4.1 Over-the-Counter (OTC) Drugs
3.4.2 Respiratory Drugs
3.4.3 Diabetes Drugs
4.2 Market Segmentation
4.3 PEST Analysis
4.4 Porter 5 (Five) Forces
126.96.36.199 Increasing incidence of lung cancer cases across the globe
188.8.131.52 Recent drug approvals and collaborations to develop new products
184.108.40.206 Increasing R&D spending for the development of new products
220.127.116.11 Rapid industrialization leading to increasing pollution
18.104.22.168 High treatment cost
22.214.171.124 Patent loss of key drugs to slow down the pace of the market
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6.2 Small Cell Lung Cancer (SCLC)
6.3 Non-Small Cell Lung Cancer (NSCLC)
7.2 Small Molecules
8.2 North America
8.4 Asia Pacific
8.5 Rest of the World
10.1.2 Business Units
10.1.3 Geographic Revenue
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategies
10.2 AstraZeneca PLC
10.2.2 Business Units
10.2.3 Geographic Revenue
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Pfizer, Inc.
10.3.2 Business Units
10.3.3 Geographic Revenue
10.3.4 Business Focus
10.3.5 SWOT Analysis
10.3.6 Business Strategies
10.4 Eli Lilly & Company Ltd
10.4.2 Business Units
10.4.3 Geographic Revenue
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategies
10.5 Novartis AG
10.5.2 Business Units
10.5.3 Geographic Revenue
10.5.4 Business Focus
10.5.5 SWOT Analysis
10.5.6 Business Strategy
11.2 GlaxoSmithKline plc
11.3 Merck & Co., Inc.
11.4 Sanofi S.A.
11.5 Celgene Corporation
Table 2 Top 10 Pharma Companies by Revenue ($Billion)
Table 3 Top Pharma Drugs by Sales ($Million)
Table 4 List of Oncology Drugs Approved (2017 & 2018)
Table 5 Global Lung Cancer Drugs Market Revenue by Regions, 2018–2025 ($Billion)
Table 6 Other Vendors of Lung Cancer Drugs Market
Table 7 F. Hoffmann-La Roche Ltd.: Product Offerings
Table 8 F. Hoffmann-La Roche Ltd.: Recent Developments
Table 9 AstraZeneca Plc: Product Offerings
Table 10 AstraZeneca Plc: Recent Developments
Table 11 Pfizer Inc.: Product Offerings
Table 12 Pfizer Inc.: Recent Developments
Table 13 Eli Lilly & Company Ltd.: Product Offerings
Table 14 Eli Lilly & Company Ltd.: Recent Developments
Table 15 Novartis AG: Product Offerings
Table 16 Novartis AG: Recent Developments
Table 17 Bristol-Myers Squibb: Snapshot
Table 18 Bristol-Myers Squibb: Recent Developments
Table 19 GlaxoSmithKline Plc: Snapshot
Table 20 GlaxoSmithKline Plc: Recent Developments
Table 21 Merck & Co., Inc.: Snapshot
Table 22 Merck & Co., Inc.: Recent Developments
Table 23 Sanofi: Snapshot
Table 24 Sanofi: Recent Developments
Table 25 Celgene Corporation: Snapshot
Table 26 Celgene Corporation: Recent Developments
Chart 2 Research Methodology of Global Lung Cancer Drugs Market
Chart 3 Global Lung Cancer Drugs Market Revenue, 2018–2025 ($Billion)
Chart 4 Segmentation of Global Lung Cancer Drugs Market
Chart 5 Pest Analysis of Global Lung Cancer Drugs Market
Chart 6 Porter 5 Forces on Global Lung Cancer Drugs Market
Chart 7 Market Dynamics – DRO Analysis
Chart 8 DRO – Impact Analysis of Global Lung Cancer Drugs Market
Chart 9 Key Stakeholders
Chart 10 Global Lung Cancer Drugs Market by Disease Type Segmentation, 2018 (%)
Chart 11 Global Lung Cancer Drugs Market by Disease Type Segmentation, 2025 (%)
Chart 12 Global Small Cell Lung Cancer Market Forecast, 2018–2025 ($Billion)
Chart 13 Global Non-Small Cell Lung Cancer Market Forecast, 2018–2025 ($Billion)
Chart 14 Global Lung Cancer Drugs Market by Molecule Type Segmentation, 2018 (%)
Chart 15 Global Lung Cancer Drugs Market by Molecule Type Segmentation, 2025 (%)
Chart 16 Global Small Molecules Market Forecast, 2018–2025 ($Billion)
Chart 17 Global Biologics Market Forecast, 2018–2025 ($Billion)
Chart 18 Global Lung Cancer Drugs Market by Geographical Segmentation, 2018 (%)
Chart 19 Global Lung Cancer Drugs Market by Geographical Segmentation, 2025 (%)
Chart 20 Lung Cancer Drugs Market Revenue In North America, 2018–2025 ($Billion)
Chart 21 Lung Cancer Drugs Market Revenue In Europe, 2018–2025 ($Billion)
Chart 22 Lung Cancer Drugs Market Revenue In Asia Pacific, 2018–2025 ($Billion)
Chart 23 Lung Cancer Drugs Market Revenue In Rest of The World, 2018–2025 ($Billion)
Chart 24 F. Hoffmann-La Roche Ltd.: Overview Snapshot
Chart 25 F. Hoffmann-La Roche Ltd.: Business Units
Chart 26 F. Hoffmann-La Roche Ltd.: Geographic Revenue
Chart 27 F. Hoffmann-La Roche Ltd.: SWOT Analysis
Chart 28 AstraZeneca Plc: Overview Snapshot
Chart 29 AstraZeneca Plc: Business Units
Chart 30 AstraZeneca Plc: Geographic Revenue
Chart 31 AstraZeneca Plc: SWOT Analysis
Chart 32 Pfizer Inc.: Overview Snapshot
Chart 33 Pfizer Inc.: Business Units
Chart 34 Pfizer Inc.: Geographic Revenue
Chart 35 Pfizer Inc: SWOT Analysis
Chart 36 Eli Lilly & Company Ltd.: Overview Snapshot
Chart 37 Eli Lilly & Company Ltd.: Business Units
Chart 38 Eli Lilly & Company Ltd.: Geographic Revenue
Chart 39 Eli Lilly & Company Ltd.: SWOT Analysis
Chart 40 Novartis AG: Overview Snapshot
Chart 41 Novartis AG: Business Units
Chart 42 Novartis AG: Geographical Revenue
Chart 43 Novartis AG: SWOT Analysis
- AstraZeneca PLC
- Bristol-Myers Squibb
- Celgene Corporation
- Eli Lilly & Company Ltd
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- Takeda Pharmaceutical